Polymyxin B Inj Rx
Generic Name and Formulations:
Polymyxin B sulfate 500,000units/vial; pwd for IM, intrathecal inj, IV drip or ophthalmic use after reconstitution.
Various generic manufacturers
Indications for Polymyxin B Inj:
Susceptible infections due to P. aeruginosa including UTIs, meninges, bloodstream, and eye infections. Other serious susceptible infections including H. influenza meningeal, E. coli UTIs, and bacteremia due to A. aerogenes and K. pneumoniae.
Adults and Children:
Infants: up to 40,000units/kg per day IV or IM inj. Adults and children: IV: 15,000–25,000units/kg per day in divided doses every 12 hours; max 25,000units/kg per day. IM: 25,000–30,000units/kg per day in divided doses every 4–6 hours. P. aeruginosa meningitis: Give by intrathecal inj only. <2yrs: 20,000units once daily for 3–4 days or 25,000units once every other day, continue with 25,000units once every other day; >2yrs: 50,000units once daily for 3–4 days, then 50,000units once every other day; both: treat for at least 2 weeks after negative CSF cultures and sugar content normalized. Ophthalmic: see literature. Renal impairment: adjust or reduce dose.
Renal impairment. Monitor renal function before and during therapy; discontinue if nephrotoxicity occurs. Pregnancy: not recommended.
Avoid other neurotoxic and/or nephrotoxic drugs (eg, bacitracin, aminoglycosides, colistin). May potentiate neuromuscular blockade with anesthetics and/or muscle relaxants.
Nephrotoxicity (eg, albuminuria, azotemia, cylindruria), neurotoxicity (eg, flushing, dizziness, paresthesias), meningeal irritation (intrathecal), drug fever, rash, inj site pain, thrombophlebitis; respiratory paralysis (discontinue if occurs).
Formerly known under the brand name Aerosporin.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|